Last, we found that P-selectin–targeted nanoPROTACs encapsulating degraders of BRD4 and MEK1/2 led to enhanced tumor localization over normal tissue, efficient target degradation, and significantly improved antitumor efficacy in murine solid tumor models. The gene discussed is BRD4; the disease is neoplasm.